Investigational drug · Phase 3
Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Anti IL-6R, Idiopathic Multicentric Castleman's Disease, Castleman's Disease, Multicentric.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
8
Any phase or sponsor naming "Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody"
First trial start
2022
Apr 18, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody", any sponsor or status.
Conditions studied
As listed on its trial records.
- Anti IL-6R
- Idiopathic Multicentric Castleman's Disease
- Castleman's Disease, Multicentric
- Rheumatoid Arthritis (RA)
Approved drugs for the same conditions: Rheumatoid arthritis · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody" as an intervention, largest first.
Zhejiang Hisun Pharmaceutical Co. Ltd.Industry
NCT06048224 · 669 participants · Start Dec 28, 2020 · Primary completion Sep 14, 2021
Drug: HS628+MTX; Actemra +MTX · For: Moderate to Severe Active Rheumatoid Arthritis
Sites: Beijing, China
- Phase III Trial of VDJ001 In Patients With Moderate-to-severe Active Rheumatoid ArthritisPivotal-lookingEnrolling by invitation
Beijing VDJBio Co., LTD.Industry
NCT06726096 · 615 participants (planned) · Start Apr 9, 2025 · Primary completion Apr 20, 2026
Drug: Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection · For: Rheumatoid Arthritis (RA); Anti IL-6R
Sites: Beijing, China
- Phase II Trial of VDJ001 in Patients With Moderate-to-severe Active Rheumatoid ArthritisPivotal-lookingCompleted
Beijing VDJBio Co., LTD.Industry
NCT05957107 · 181 participants · Start May 26, 2022 · Primary completion Jun 2, 2023
Drug: Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection · For: Rheumatoid Arthritis
Sites: Beijing, China; Baoji, China; Bengbu, China · 15 sites in all
- Phase III Trial of VDJ001 In Patients With Idiopathic Multicentric Castleman DiseasePivotal-lookingRecruiting
Beijing VDJBio Co., LTD.Industry
NCT07872423 · 45 participants (planned) · Start Jan 27, 2025 · Primary completion Jun 9, 2027
Drug: Recombinant Humanized Anti-Interleukin-6 Receptor Monoclonal Antibody Injection; Placebo · For: Anti IL-6R; Castleman's Disease, Multicentric
Sites: Beijing, China; Xiamen, China; Wuhan, China · 8 sites in all
- A Prospective Study of Tocilizumab in the Treatment of Idiopathic Retroperitoneal FibrosisStatus unknown
Peking Union Medical College HospitalAcademic, hospital or other
NCT04762784 · 40 participants (planned) · Start Jul 1, 2020 · Primary completion Feb 10, 2023
Drug: Tocilizumab; Glucocorticoids · For: Idiopathic Retroperitoneal Fibrosis
Sites: Beijing, China
The Affiliated Hospital of Qingdao UniversityAcademic, hospital or other
NCT06021574 · 40 participants · Start Jun 28, 2019 · Primary completion Jan 6, 2020
Drug: VDJ001; Placebo · For: Healthy
Sites: Qingdao, China
- A Study of Anti-IL-6R mAb Injection in Patients With iMCDActive, not recruiting
Beijing VDJBio Co., LTD.Industry
NCT05345522 · 25 participants · Start Apr 18, 2022 · Primary completion Nov 27, 2022
Drug: Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4 mg/kg, q2w; Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 6 mg/kg, q2w and 3 more · For: Idiopathic Multicentric Castleman's Disease
Sites: Beijing, China; Chengdu, China · 3 sites in all
Brian MillerAcademic, hospital or other
NCT01696929 · 8 participants · Start Sep 2012 · Primary completion Dec 2014
Drug: Tocilizumab · For: Schizophrenia
Sites: Augusta, Georgia
Newest research
PubMed records naming it or its code names, newest first.
- Tolerability, safety, and pharmacokinetics of a single intravenous administration of a novel recombinant humanized anti-interleukin-6 receptor monoclonal antibody in healthy Chinese volunteers.
Jiang X, Lin P, Sun F, et al. · Front Pharmacol 2023
- The Role of Tocilizumab in Glucocorticoid Resistant Giant Cell Arteritis: A Case Series and Literature Review.
Stretton B, Tan Y, Hassall M, et al. · J Neuroophthalmol 2023
- Anti-interleukin-6 monoclonal antibody for cytokine storm in COVID-19.
Douedi S, Chaudhri M, Miskoff J · Ann Thorac Med 2020
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.